The goal of this clinical trial is to explore the value of molecular residual disease (MRD) monitoring based on ctDNA in borderline resectable or locally advanced pancreatic cancer. The main questions it aims to answer are: * prognostic value of baseline MRD; * the role of MRD dynamic changes after treatment in guiding treatment. Peripheral blood derived from participants will be obtained for MRD test before conversion therapy initiation and at the first imaging assessment after chemotherapy.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
100
Another chemotherapy regimen, targeted therapy, or immunotherapy
Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, China
RECRUITINGResection rate
Proportion of patients who receive surgical resection
Time frame: Baseline until operation, PD or death, whichever occurs first (up to approximately 24 months)
Overall survival
The date of conversion therapy initiation to death due to any cause.
Time frame: Baseline until PD or death, whichever occurs first (up to approximately 24 months)
Progression-free survival
The date of conversion therapy initiation to tumor progression or death due to any cause in the absence of progression.
Time frame: Baseline until PD or death, whichever occurs first (up to approximately 24 months)
R0 resection rate
Proportion of patients who receive R0 surgical resection
Time frame: Baseline until operation, PD or death, whichever occurs first (up to approximately 24 months)
Major pathological response
≤10% of the viable tumor cell in resected sample
Time frame: Baseline until operation, PD or death, whichever occurs first (up to approximately 24 months)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.